Enanta Pharmaceuticals (ENTA) Operating Income (2016 - 2025)
Historic Operating Income for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to -$18.4 million.
- Enanta Pharmaceuticals' Operating Income rose 3841.36% to -$18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$85.3 million, marking a year-over-year increase of 2986.42%. This contributed to the annual value of -$85.3 million for FY2025, which is 2986.42% up from last year.
- According to the latest figures from Q3 2025, Enanta Pharmaceuticals' Operating Income is -$18.4 million, which was up 3841.36% from -$18.9 million recorded in Q2 2025.
- Over the past 5 years, Enanta Pharmaceuticals' Operating Income peaked at -$18.4 million during Q3 2025, and registered a low of -$39.5 million during Q1 2023.
- In the last 5 years, Enanta Pharmaceuticals' Operating Income had a median value of -$30.4 million in 2021 and averaged -$29.8 million.
- Its Operating Income has fluctuated over the past 5 years, first plummeted by 15010.53% in 2021, then surged by 3841.36% in 2025.
- Over the past 5 years, Enanta Pharmaceuticals' Operating Income (Quarter) stood at -$30.4 million in 2021, then rose by 1.3% to -$30.0 million in 2022, then dropped by 16.24% to -$34.9 million in 2023, then surged by 32.51% to -$23.5 million in 2024, then rose by 21.9% to -$18.4 million in 2025.
- Its Operating Income was -$18.4 million in Q3 2025, compared to -$18.9 million in Q2 2025 and -$24.5 million in Q1 2025.